Angioedema induced by cardiovascular drugs: new players join old friends

Citations Over TimeTop 10% of 2015 papers

Abstract

During the last years, two new cardiovascular drug classes, namely inhibitors of DPP IV or neprilysin, have been developed. In both cases, there is clinical evidence for their potential to induce angioedema as known already from blockers of the renin-angiotensin-aldosterone system (RAAS). The majority of angioedema induced by DPP IV inhibitors occurs during concomitant treatment with ACEi and is therefore likely mediated by overactivation of bradykinin type 2 receptors (B2). In striking contrast, the molecular pathways causing angioedema induced by neprilysin inhibitors, that is, sacubitril, are unclear, although a contribution of bradykinin appears likely. Nevertheless, there is no clinical evidence suggesting that inhibition of B2 might relieve the symptoms and/or prevent invasive treatment including coniotomy or tracheotomy in angioedema caused by these drugs. Therefore, the risk of angioedema should always be considered, especially in ambulatory care situations where patients have no rapid access to intensive care.

Related Papers

• → Hereditary Angioedema with Normal C1 Inhibitor: Clinical Symptoms and Course(2007)134 cited
• → A Case Report of Angioedema During Long-term (66 Months) Angiotensin Converting Enzyme Inhibition Therapy With Enalapril(1996)16 cited
• → Preliminary results of a non-interventional single-center study evaluating the efficacy of long-term use of lanadelumab in routine clinical practice in the Russian Federation(2023)2 cited
• → Complement Component Analysis in Angioedema(1975)11 cited
• [Angioedema caused by enalapril].(1991)